Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28845941 | 1.00 | APLNR (0.34) | APLNRMAPTCYP2C19POLBGABRP | |
| Hydrochloric Acid SCHEMBL9779724 | 0.98 | APLNR (0.33) | APLNRMAPTCYP2C19POLB | |
| SCHEMBL7581401 | 0.80 | — | — | |
| SCHEMBL29118311 | 0.80 | EPHX1 (0.32) | — | |
| SCHEMBL1818943 | 0.73 | APLNR (0.39) | APLNRCYP2C19GABRPGABRDGABRA1 | |
| SCHEMBL29020333 | 0.73 | APLNR (0.39) | APLNRCYP2C19GABRPGABRDGABRA1 | |
| SCHEMBL29020335 | 0.68 | APLNR (0.34) | APLNRCYP2C19GABRPGABRDGABRA1 | |
| SCHEMBL15791000 | 0.67 | NOS3 (0.31) | — | |
| SCHEMBL19979162 | 0.67 | NOS3 (0.31) | — | |
| SCHEMBL13381001 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102633767-B | Preparation method of non-ionic type iodine contrast medium intermediate 2-isopropyl-5-carboxy-1, 3-dioxane | WUHAN INST TECHNOLOGY | 2013-10-30 | — | — | CN | claimed |
| CN-117658849-A | Iobixin crystal form II and preparation method thereof | 成都倍特药业股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-116120201-A | Improved method for synthesizing iobialcohol | 重庆圣华曦药业股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3580199-B1 | METHOD FOR THE ONE-POT PRODUCTION OF ORGANO-IODINATED COMPOUNDS | GUERBET SA (FR) | 2023-04-05 | — | — | EP | disclosed |
| CN-110267937-B | Method for producing organic iodinated compound by one-pot method | 法国加柏公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-108929304-B | Preparation method of trans-2-substituent-5-carboxyl-1, 3-dioxane | 正大天晴药业集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-109134289-B | Synthetic method and application of contrast agent intermediate | 成都西岭源药业有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | GUERBET (FR) | 2020-11-17 | — | — | US | disclosed |
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | GUERBET (FR) | 2020-11-17 | — | — | US | disclosed |
| CN-110903275-A | Process for producing iobitridol, intermediate therefor, and process for producing the same | 苏州科伦药物研究有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-102633767-B | Preparation method of non-ionic type iodine contrast medium intermediate 2-isopropyl-5-carboxy-1, 3-dioxane | WUHAN INST TECHNOLOGY | 2013-10-30 | — | — | CN | disclosed |
| CN-102633767-A | Preparation method of non-ionic type iodine contrast medium intermediate 2-isopropyl-5-carboxy-1, 3-dioxane | WUHAN INST TECHNOLOGY | 2012-08-15 | — | — | CN | disclosed |
| CN-102633767-A | Preparation method of non-ionic type iodine contrast medium intermediate 2-isopropyl-5-carboxy-1, 3-dioxane | WUHAN INST TECHNOLOGY | 2012-08-15 | — | — | CN | disclosed |
| EP-1019404-A4 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMW SCIENT IND RES ORG (AU) | 2001-07-04 | — | — | EP | disclosed |
| EP-1019404-A1 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999012927-A1 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-03-18 | — | — | WO | disclosed |
| US-5618977-A | Polyiodinated compounds, process of preparation and contrast agent containing them | GUERBET S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| US-5043152-A | Radiography | GUERBET S.A. (FR) | 1991-08-27 | — | — | US | disclosed |
| US-4725620-A | 2H-pyran-2,6-(3H)-dione derivatives with anti-allergic activity | ALLERGAN, INC. (US) | 1988-02-16 | — | — | US | disclosed |
| US-4521327-A | STRESS RESISTANCE, PHOTOSTABILITY, ELECTRICAL RESISTANCE, LOW BIREFRINGENCE | VEB WERK FUR FERNSEHELEKTRONIK IM VEB KOMBINAT MIKROELEKTRONIK (DD) | 1985-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | TPO, NISCH, PPIP5K2 | APLNR 3223/4885MAPT 3911/4885CYP2C19 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.